Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 9
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 9

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderRenovoRx · 51
Strongest available pathXeris Pharmaceuticals · +244.5%
Widest latest marginLigand Pharmaceuticals · 46.4%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1RNXT · Nasdaq

RenovoRx

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2009Los Altos, California$87.1M market cap
View full Companies Radar profile
51Moderate
Snapshot price$1.93as of page date
Monthly-close return-68.0%five-year window
FY2025 revenue$0.00BRenovoRx, Inc.
Net margin-994.5%FY2025
P/E snapshot-16.1xone ratio, not a verdict
Prism attention5.1%share across these five
Filing track recordRevenue, USD billions
+2511.6%
$0$0.0B$0.0B$0.0BFY2024: $0.000BFY2025: $0.001B20242025
FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2511.6%
52-week position97% through range
$0.70$1.97
News mentions429
Community mentions0partial coverage
U.S.-scope patents33
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal81/100
Management stability90/100
Market position0/100
Capital-event signal50/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2TCRT · Nasdaq

Ziopharm Oncology

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1998Houston, Texas$4.3M market cap
View full Companies Radar profile
51Moderate
Snapshot price$1.70as of page date
Monthly-close return-99.4%five-year window
FY2025 revenue$0.00BAlaunos Therapeutics, Inc.
Net margin-83520.0%FY2025
Prism attention8.1%share across these five
Filing track recordRevenue, USD billions
-98.7%
$0$0.0B$0.0B$0.0BFY2021: $0.000BFY2022: $0.003BFY2023: $0.000BFY2024: $0.000BFY2025: $0.000B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -66.5%
52-week position5% through range
$1.55$4.59
News mentions675
Community mentions9partial coverage
U.S.-scope patents160
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal69/100
Management stability90/100
Market position0/100
Capital-event signal74/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3LGND · Nasdaq

Ligand Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1987San Diego, California$5.66B market cap
View full Companies Radar profile
50Moderate
Snapshot price$284.1as of page date
Monthly-close return+226.9%five-year window
FY2025 revenue$0.27BLIGAND PHARMACEUTICALS INC
Net margin46.4%FY2025
P/E snapshot29.2xone ratio, not a verdict
Prism attention29.9%share across these five
Filing track recordRevenue, USD billions
-3.3%
$0$0.1B$0.2B$0.3BFY2021: $0.277BFY2022: $0.196BFY2023: $0.131BFY2024: $0.167BFY2025: $0.268B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -0.8%
52-week position74% through range
$160.8$326.6
News mentions2.5K
Community mentions81partial coverage
U.S.-scope patents15
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal57/100
Management stability90/100
Market position23/100
Capital-event signal62/100
Innovation pulse9/100
Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 12 M&A involvements, 11 asset-acquisition events and 9 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4UTHR · Nasdaq

United Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1998Silver Spring, Maryland$21.89B market cap
View full Companies Radar profile
50Moderate
Snapshot price$510.4as of page date
Monthly-close return+176.5%five-year window
FY2025 revenue$3.18BUNITED THERAPEUTICS Corp
Net margin41.9%FY2025
P/E snapshot18.3xone ratio, not a verdict
Prism attention50.7%share across these five
Filing track recordRevenue, USD billions
+36.7%
$0$1.1B$2.1B$3.2BFY2023: $2.328BFY2024: $2.877BFY2025: $3.183B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 16.9%
52-week position58% through range
$375.6$609.4
News mentions4.2K
Community mentions95partial coverage
U.S.-scope patents786
Prism Insights

What sits behind the readiness signal

Observed risk 2/100higher means more observed risk
Earnings signal59/100
Management stability90/100
Market position17/100
Capital-event signal74/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 9 M&A involvements, 3 asset-acquisition events and 6 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5XERS · U.S. exchange

Xeris Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2005Chicago, Illinois$1.54B market cap
View full Companies Radar profile
50Moderate
Snapshot price$8.44as of page date
Monthly-close return+244.5%five-year window
FY2025 revenue$0.29BXeris Biopharma Holdings, Inc.
Net margin0.2%FY2025
P/E snapshot21.6xone ratio, not a verdict
Prism attention6.2%share across these five
Filing track recordRevenue, USD billions
+492.2%
$0$0.1B$0.2B$0.3BFY2021: $0.049BFY2022: $0.110BFY2023: $0.164BFY2024: $0.203BFY2025: $0.292B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 56.0%
52-week position66% through range
$5.25$10.08
News mentions523
Community mentions12partial coverage
U.S.-scope patents249
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal71/100
Management stability90/100
Market position10/100
Capital-event signal59/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 7 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Xeris Pharmaceuticals
+244.5%
Ligand Pharmaceuticals
+226.9%
United Therapeutics
+176.5%
RenovoRx
-68.0%
Ziopharm Oncology
-99.4%

Latest revenue

USD billions, official filing scope shown on each company card.

United Therapeutics
$3.18B
Xeris Pharmaceuticals
$0.29B
Ligand Pharmaceuticals
$0.27B
RenovoRx
$0.00B
Ziopharm Oncology
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Ligand Pharmaceuticals
46.4%
United Therapeutics
41.9%
Xeris Pharmaceuticals
0.2%
RenovoRx
-994.5%
Ziopharm Oncology
-83520.0%

Prism news attention

Normalized share across these five names; attention is not quality.

United Therapeutics
50.7%
Ligand Pharmaceuticals
29.9%
Ziopharm Oncology
8.1%
Xeris Pharmaceuticals
6.2%
RenovoRx
5.1%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

United Therapeutics leads the conversation

It holds 50.7% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $3.18B.

Price path

Xeris Pharmaceuticals leads the available price paths

Its monthly-close return is +244.5% for the five-year window. At the other end, Ziopharm Oncology is -99.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Ligand Pharmaceuticals has the widest latest margin

Its FY2025 net margin is 46.4%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

RenovoRx shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -16.1x while its five-year window price return is -68.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · LGND

Ligand Pharmaceuticals

2,505available Prism news records

Prism top themes

Capital allocation & transactions
99
Price action & investor response
54
Leadership & governance
35
Legal, arbitration & regulatory
31
Earnings & financial performance
21

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-51.3%344 latest 12m vs 706 prior 12m
2024-01: 9 mentions2024-02: 34 mentions2024-03: 17 mentions2024-04: 16 mentions2024-05: 27 mentions2024-06: 7 mentions2024-07: 24 mentions2024-08: 11 mentions2024-09: 10 mentions2024-10: 17 mentions2024-11: 11 mentions2024-12: 9 mentions2025-01: 5 mentions2025-02: 572 mentions2025-03: 11 mentions2025-04: 19 mentions2025-05: 12 mentions2025-06: 5 mentions2025-07: 7 mentions2025-08: 24 mentions2025-09: 15 mentions2025-10: 20 mentions2025-11: 17 mentions2025-12: 10 mentions2026-01: 5 mentions2026-02: 10 mentions2026-03: 24 mentions2026-04: 60 mentions2026-05: 34 mentions2026-06: 118 mentions2024-012026-06

Machine-classified coverage tone

98.2% positive+3.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

generic drug approval 18angel investors 18stock performance 17angiogenesis inhibitors 14startup valuation 11merger update 10biotech incubator 10stock price 9

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-02–2026-06-13 · trend and themes shown through 2026-06
Areas of research · UTHR

United Therapeutics

4,239available Prism news records

Prism top themes

Price action & investor response
198
Capital allocation & transactions
127
Legal, arbitration & regulatory
68
Earnings & financial performance
67
Leadership & governance
38

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-1.0%711 latest 12m vs 718 prior 12m
2024-03: 30 mentions2024-04: 50 mentions2024-05: 38 mentions2024-06: 22 mentions2024-07: 28 mentions2024-08: 37 mentions2024-09: 18 mentions2024-10: 29 mentions2024-11: 38 mentions2024-12: 56 mentions2025-01: 72 mentions2025-02: 186 mentions2025-03: 38 mentions2025-04: 69 mentions2025-05: 51 mentions2025-06: 55 mentions2025-07: 50 mentions2025-08: 56 mentions2025-09: 112 mentions2025-10: 43 mentions2025-11: 57 mentions2025-12: 22 mentions2026-01: 54 mentions2026-02: 84 mentions2026-03: 91 mentions2026-04: 123 mentions2026-05: 111 mentions2026-06: 13 mentions2026-07: 0 mentions2026-08: 1 mentions2024-032026-08

Machine-classified coverage tone

95.8% positive+8.2 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

share price 38stock price 36company valuation 35generic drug approval 23startup valuation 21stock performance 20earnings report 15stock surge 12

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-10–2026-08-01 · trend and themes shown through 2026-08
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

LGND

Ligand Pharmaceuticals

81 mentions
Stock and valuation
28
Products, pricing and logistics
22

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 81 records remained after filtering.

UTHR

United Therapeutics

95 mentions
Stock and valuation
33
Products, pricing and logistics
20
Workplace and hiring
6

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 95 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

RNXT

RenovoRx

through 2026-03-31
Company announcements 7Earnings releases 5Business contracts 1Listing / IPO 1
  1. Earnings releases

    Revenue for the year ended December 31, 2025, was $1.1 million, compared to $43,000 for the year ended December 31, 2024.

  2. Company announcements

    RenovoRx reported that utilization of RenovoCath devices by its initial customers announced this past December has led to repeat purchase orders.

  3. Business contracts

    RenovoRx, Inc. (NASDAQ: RNXT) recently announced the execution of an underwriting agreement with Titan Partners Group LLC for a firm commitment underwritten public offering of its common stock.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TCRT

Ziopharm Oncology

through 2025-02-14
Listing / IPO 3
  1. Listing / IPO

    Ziopharm Oncology Inc., of Boston, priced a follow-on offering of about 9.7 million shares at $5.15 per share to a single institutional investor. Proceeds are expected to be $50 million and will be used for general corporate and working capital purposes, including the advancement of its clinical programs.

  2. Listing / IPO

    Taking advantage of a modest stock bump following its presentation at the J.P. Morgan Healthcare Conference earlier this month, Ziopharm Oncology Inc. priced a $50.2 million public offering to support ongoing work with late-stage programs, including palifosfamide and a DNA therapeutic gained via last year's partnership with Intrexon Corp.

  3. Listing / IPO

    Ziopharm Oncology Inc. priced a public offering of 10 million shares at $8.75 each.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LGND

Ligand Pharmaceuticals

through 2026-04-28
Earnings releases 21Company announcements 10Leadership changes 9Asset acquisitions 8M&A 6
  1. M&A

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has agreed to acquire XOMA Royalty Corporation (NASDAQ: XOMA) for $39.00 per share in cash

  2. Leadership changes

    Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development.

  3. Company announcements

    Deployable capital of $1 billion will drive long‑term royalty revenue growth through disciplined allocation

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

UTHR

United Therapeutics

through 2026-03-25
Earnings releases 26Lawsuits 8Business contracts 5M&A 4Regulatory 2
  1. Earnings releases

    The gross profit of United Therapeutics with headquarters in the United States amounted to ************ U.S. dollars in 2025.

  2. Lawsuits

    United Therapeutics and Liquidia have been engaged in a legal fight related to United’s ‘327 patent as United has been trying to keep a Tyvaso competitor called Yutrepia off the market.

  3. Listing / IPO

    United Therapeutics Corp. (UTHR)40 2/10/05 5S $44.57 N/A N/A $222.9

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

XERS

Xeris Pharmaceuticals

through 2026-01-09
Earnings releases 2Listing / IPO 2Leadership changes 1
  1. Earnings releases

    Based on Xeris Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $74.38 million and a net profit of $621 thousand.

  2. Leadership changes

    Mr. Edick most recently served as the Chairman and Chief Executive Officer of Xeris Pharmaceuticals from January 2017 until his retirement in August 2024, when he moved into a senior advisory role with the company.

  3. Listing / IPO

    Xeris Pharmaceuticals Inc. closed its IPO for gross proceeds of approximately $98.3 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 41–48. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

RenovoRx has the widest attention-readiness rank gap

It ranks #5 by measured news attention (5.1%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open RenovoRx in Companies Radar

RenovoRx shows a price-operating divergence to inspect

Its displayed filing-revenue change is +2511.6% while its available monthly-close return is -68.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open RenovoRx in Companies Radar
Explanations

Attention measures coverage volume, not quality

United Therapeutics's 50.7% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open United Therapeutics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open RenovoRx's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 51/100 score.

Open RenovoRx in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon